Anti-CSPG4 fusions with interferon for the treatment of malignancy
AssigneeThe Regents of the University of California
InventorsSherie L. Morrison, John M. Timmerman, Kham M. Trinh
Life of this patent
Estimating the term…
Abstract
In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha or to an interferon beta (IFN-β) or to a mutant interferon beta, or to an interferon gamma (IFN-γ) or to a mutant interferon gamma.
Claims11
A chimeric construct comprising an interferon attached to a full-length antibody that binds chondroitin sulfate proteoglycan 4 (CSPG4), where:
- said interferon is attached to said antibody by a peptide linker comprising the amino acid sequence LEPKSSDKTHTSPPSPGG (SEQ ID NO:75);
- said interferon is a mature interferon alpha 2 (SEQ ID NO:
- 12), or a mutant mature interferon alpha 2 comprising one or more mutations selected from the group consisting of E58A, E58L, E58N, H57A, H57M, H57Y, Q61A, Q61D, and Q61S relative to mature interferon alpha 2;
- and said construct when contacted to a cell that expresses or overexpresses CSPG4 cell results in the killing or inhibition of growth or proliferation of said cell.
Dependencies are inferred from the claim text.